ASX Health Stocks: Recce can now dose R327 at higher level, testing its high concentration potential

Recce Pharma cleared to increase R327’s minimum dose
R327 can now be administered at 4,000mg over a fast infusion of 30 minutes
ResMed has had a solid Q3

Recce Pharma cleared to increase drug dose

Recce Pharmaceuticals (ASX:RCE) says an independent Safety Committee has unanimously cleared an increase of Recce327 (R327) to 4,000mg (I.V.) over a fast infusion of 30 minutes.

The approval came after the company has previously tested dosing at 3,000mg at multiple infusion times; 15 mins, 20 mins, 30 mins, 45 mins, and 1 hour.

Recce has now identified 30 minutes as the potential optimum infusion time for 4,000mg, as the company investigates R327’s high concentration potential.

R327 is one of Recce’s anti-infective pipelines used as an intravenous and topical therapy being developed for the treatment of serious and potentially life-threatening infections.

The drug is currently being studied in the ongoing Phase I/II study of the IV formulation in healthy volunteers and in patients with uncomplicated or recurrent urinary tract infections (UTIs).

In a parallel clinical program, R327 applied topically against Diabetic Foot Ulcer Infections recently demonstrated its efficacious potential against a broad range of antibiotic-resistant infections.

The potential of R327 via I.V. administration will now be made available at the completion of this human clinical trial in line with study protocol.

CEO James Graham says he’s thrilled the independent safety committee has unanimously clearly an increased R327 dose to 4,000mg, over a 30-minute fast I.V. infusion.

“The high concentration potential to administer a broad spectrum anti-infective underscores the potential of a novel treatment for millions of patients worldwide that suffer from Urinary Tract Infection/Urosepsis each year,” Graham said.

ResMed has had a solid quarter

Meanwhile, sleep device and digital health company ResMed (ASX:RMD) has had a solid Q3 FY24.

In the quarter, revenue increased by 7% on pcp to $1.2 billion.

Gross margin grew 260 bps to 57.9%; and income from operations increased 25% to $374.6m.

During the quarter, ResMed paid $70 million in dividends and repurchased 261,000 shares for a total of $50 million as part of its ongoing capital management.